Advanced Code injection

Ontario Industry Updates

NOVADAQ Enters Into Agreement to be Acquired by Stryker Corporation

NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ) the leading provider of proven comprehensive fluorescence imaging solutions that improve clinical outcomes and reduce healthcare costs in minimally invasive and open surgeries, today announced that it has entered into a definitive arrangement  with Stryker Corporation to acquire all of the issued and outstanding shares of NOVADAQ.

Lumira Capital Launches Philanthropy Initiative with Leading Canadian Healthcare Foundations

TORONTO, June 6, 2017 ‐ Lumira Capital, a leading North American healthcare venture capital firm, announced today that it has launched a new philanthropic initiative whereby the firm’s partners will donate a portion of their profit share from Lumira Capital IV L.P. to up to fifteen leading healthcare foundations in Canada.

Reminder! Call for CTA@Boston Applications - Deadline is June 12

Are you a High Potential Canadian ICT or Life Science SME ready to grow in the US Boston Market? We can help.

CTA@Boston is an award-winning program that connects Canadian ICT and Life Science companies to US clients, strategic partners and investors, emphasizing aggressive business development and growth.  

The Canadian Technology Accelerator in Boston (CTA@Boston) is looking for fast growing ICT and Life Science candidates for the Fall 2017 cohort.

Apply Now to CTA@Boston

Application Deadline:  June 12, 2017

Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors

Formation Biologics, a clinical stage biopharmaceutical company, today announces the start of a multi-center, Phase I/IIa trial evaluating AVID100 in patients with epidermal growth factor receptor (EGFR)-expressing malignancies. The trial commenced at South Texas Accelerated Research Therapeutics in San Antonio, Texas.